Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Damora Therapeutics Q3 2026 Results: Net Loss of $32M, Loss Widens

Damora Therapeutics reported a significant increase in operating expenses for the nine months ended September 30, 2026, totaling $102.7 million compared to $9.2 million in the prior year, primarily driven by R&D for candidates DMR-001, DMR-002, and DMR-003. The company ended the period with $528.5 million in cash and marketable securities following a substantial increase in ordinary shares outstanding to 61.9 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-32.0-3.1
Net income-32.0-3.1
EPS (diluted, $ a share)$-0.40$-2.36

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: DMRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Damora Therapeutics, Inc.: key numbers

Share price
$22.56Close, Nov 17
Market cap
$1.4B
Shares outstanding
61.9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Damora Therapeutics, Inc.

All →
7:01 AM ET Form 4
Insider Buying

Damora Therapeutics Director, President and CEO Jennifer Jarrett Buys $253K of Stock

Jennifer Jarrett, Director, President and CEO, bought 12,500 shares of Damora Therapeutics, Inc. at $20.23 a share, worth $253K in total on Sep 25, 2026. Shares held after the trade: 512,500 (+2.5%).

Value
$253K
Shares
12,500
Price
$20.23
Role
Director, President and CEO
Holding change
+2.5%
Trade date
Sep 25, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.